Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice

E Debourdeau; H Beylerian; V Nguyen; D Barthelmes; M Gillies; PH Gabrielle; S Vujosevic; L Otoole; M Puzo; C Creuzot-Garcher; B Wolff; V Daien; MJR Cid; C Hooper; J ODay; A Harper; HB Morros; G Garay-Aramburu; ED De Durana Santa Coloma; P Hinchcliffe; J Wong; P Lockie; D Louis; C Younan; S Fraser-Bell; R Chong; S Nothling; A Fung; M Chilov; R Chalasani; C Thompson; J Game; M Morgan; G Banerjee; C Chung; K Tang; H Cass; J Arnold; M Perks; G Michel; L Castelnovo; A Invernizzi; L Manning; MR Núñez; AC Gesto; ES Martínez; L García García; AP Sánchez; AF Hortelano; S Aparicio-Sanchis; M Acebes; D Lorenzo; J Gonzalez-Lopez; E Ciancas; MG Zamora; EA Alonso; J Sanchez; P Calvo; NM Sanz; SG Sánchez; LB Iturralde; F Ricci; MT Sempere; PC Muñoz; F Lavid; J Escobar; J Gutiérrez; AG Escobar; SG Moreno; J Zarranz-Ventura; M Figueras-Roca; R Casaroli-Marano; SA Castiella; GP Rivases; M Díaz; AB Murillo; F Ascaso; C Arruabarrena; RM Milner; F Viola; P Berdoukas; J Suarez; L Sararols; D Qatarneh; S Lake; A Luckie; Z Louw; P Beaumont; A Hunt; P Windle; N Saha; J Chen; A Amini; H Steiner

Journal article

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice

E Debourdeau, H Beylerian, V Nguyen, D Barthelmes, M Gillies, PH Gabrielle, S Vujosevic, L Otoole, M Puzo, C Creuzot-Garcher, B Wolff, V Daien, MJR Cid, C Hooper, J ODay, A Harper, HB Morros, G Garay-Aramburu, ED De Durana Santa Coloma, P Hinchcliffe Show all

Ophthalmology and Therapy | Published : 2024

DOI: 10.1007/s40123-024-00983-2

Open access

Abstract

Introduction: Anti-vascular endothelial growth factor (VEGF) is generally given using pro re nata or “treat-and-extend” (T&E) regimens for neovascular age-related macular degeneration (nAMD). Randomized clinical trials have reported that T&E is superior to Pro re nata (PRN), but results from clinical trials may not always be replicated in clinical practice. Real-world data comparing T&E and PRN regimens for nAMD are limited. The objective of this work was to report 24-month outcomes of PRN versus T&E regimens for ranibizumab and aflibercept to treat nAMD in routine clinical practice. Methods: We conducted a retrospective analysis of data from a prospectively designed observational outcomes r..

View full abstract